Clinical Trial

Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Protocol Amendment History 2 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-05-28
notable Primary completion pushed: 2026-04-30 -> 2027-03 2026-05-28
Trial Details
NCT Number NCT06602193
Lead Sponsor Denali Therapeutics Inc.
Collaborators: Biogen
Conditions Parkinson Disease
Enrollment 50 participants
Start Date 2024-10-24
Primary Completion 2027-03 (estimated)
Study Completion 2028-02-28 (estimated)
Updated on ClinicalTrials.gov 2026-05-27